DK1855711T3 - Anvendelse af BAFF til behandling af Th2-medierede tilstande - Google Patents

Anvendelse af BAFF til behandling af Th2-medierede tilstande

Info

Publication number
DK1855711T3
DK1855711T3 DK06734022T DK06734022T DK1855711T3 DK 1855711 T3 DK1855711 T3 DK 1855711T3 DK 06734022 T DK06734022 T DK 06734022T DK 06734022 T DK06734022 T DK 06734022T DK 1855711 T3 DK1855711 T3 DK 1855711T3
Authority
DK
Denmark
Prior art keywords
baff
treat
mediated conditions
mediated
conditions
Prior art date
Application number
DK06734022T
Other languages
English (en)
Inventor
Charles Mackay
Fabienne Mackay
Susan Kalled
Original Assignee
Biogen Idec Inc
Garvan Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Garvan Inst Med Res filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1855711T3 publication Critical patent/DK1855711T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06734022T 2005-01-28 2006-01-27 Anvendelse af BAFF til behandling af Th2-medierede tilstande DK1855711T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64809805P 2005-01-28 2005-01-28
PCT/US2006/003127 WO2006081516A2 (en) 2005-01-28 2006-01-27 USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS

Publications (1)

Publication Number Publication Date
DK1855711T3 true DK1855711T3 (da) 2009-10-12

Family

ID=36741125

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06734022T DK1855711T3 (da) 2005-01-28 2006-01-27 Anvendelse af BAFF til behandling af Th2-medierede tilstande

Country Status (9)

Country Link
US (1) US20080254030A1 (da)
EP (1) EP1855711B1 (da)
AU (1) AU2006209237B2 (da)
CA (1) CA2596276A1 (da)
DE (1) DE602006007323D1 (da)
DK (1) DK1855711T3 (da)
HK (1) HK1110803A1 (da)
NZ (1) NZ560285A (da)
WO (1) WO2006081516A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
EP2281843B1 (en) * 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001288301A1 (en) * 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2626082C (en) * 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8211649B2 (en) * 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
US20110014190A1 (en) * 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
US8735347B2 (en) 2011-02-02 2014-05-27 Children's Hospital Medical Center Regulation of energy metabolism and obesity by modulating B cell activating factor (BAFF, BLYS) or BAFF signaling

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6541224B2 (en) * 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US20030175208A1 (en) * 1996-10-25 2003-09-18 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US6689579B1 (en) * 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US20030022239A1 (en) * 1997-06-18 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020055624A1 (en) * 1997-11-17 2002-05-09 Steven R. Wiley Tnf-delta ligand and uses thereof
US20010010925A1 (en) * 1997-11-17 2001-08-02 Steven R. Wiley Methods of detecting target nucleic acids of tnf-delta
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
EP2974736A1 (en) * 1999-01-25 2016-01-20 Biogen MA Inc. Baff, inhibitors thereof and their use in the modulation of the b-cell response
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
MXPA02001665A (es) * 1999-08-17 2003-07-14 Biogen Inc Receptor de baff (bcma) como agente inmunorregulador.
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU3495301A (en) * 2000-02-11 2001-08-20 Biogen Inc Heterologous polypeptide of the tnf family
US20040013674A1 (en) * 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
EP2281843B1 (en) * 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
US6475686B2 (en) * 2000-07-28 2002-11-05 Canon Kabushiki Kaisha Fixing method
AU2001288301A1 (en) * 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
JP4660092B2 (ja) * 2001-12-21 2011-03-30 イミユネツクス・コーポレイシヨン 組換えポリペプチド
US20030211509A1 (en) * 2002-03-26 2003-11-13 Wiley Steven R. TNF-delta ligand and uses thereof

Also Published As

Publication number Publication date
EP1855711B1 (en) 2009-06-17
DE602006007323D1 (de) 2009-07-30
CA2596276A1 (en) 2006-08-03
US20080254030A1 (en) 2008-10-16
NZ560285A (en) 2011-04-29
AU2006209237A1 (en) 2006-08-03
AU2006209237B2 (en) 2010-06-24
HK1110803A1 (en) 2008-07-25
EP1855711A2 (en) 2007-11-21
WO2006081516A2 (en) 2006-08-03
WO2006081516A3 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
DK1855711T3 (da) Anvendelse af BAFF til behandling af Th2-medierede tilstande
DK1720866T3 (da) Fremgangsmåde
ATE442776T1 (de) Flüssigformulierungen von carboxamid- arthropodiziden
DK1942938T3 (da) Anvendelse af oligouronater til behandling af slim-hyperviskositet
DK2500017T3 (da) Anvendelse af ketogene forbindelser til behandling af aldersrelateret hukommelsessvækkelse
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
DK2271642T3 (da) Pyridylinhibitorer af hedgehog signalering
BRPI0811473A2 (pt) Compostos hidrossolúveis de magnésio como agentes de limpeza e métodos de utilização dos mesmos.
DK1986633T3 (da) Behandling af duchennes muskeldystrofi
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
DK1874821T3 (da) Kombination af antistoffer med glykokortikoider til behandling af kræft
DK2329012T3 (da) Behandling af slagtilfælde under anvendelse af isolerede placentaceller
ES1063346Y (es) Andador
ATE476424T1 (de) Diazepanderivate als modulatoren von chemokinrezeptoren
DE112007000789A5 (de) Verwendung von Bora-tetraazepentalenen
DK3225251T3 (da) Modulering af pro-neurotrofinaktivitet
DE602005023266D1 (de) Azabenzofuransubstituierte thioharnstoffe als inhibitoren der virusreplikation
BRPI0817267A2 (pt) Prevenção de alergia em desmame
DK2373927T3 (da) Behandling af forbrændingsgas fra affaldsbehandling
DK2111555T3 (da) Diagnosticering af præeklampsi
BRPI0915394A2 (pt) purificação de citoquinas modificadas
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
BRPI0813830A2 (pt) Purificação de polipeptídeos peguilados
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
FI20065834A0 (fi) Iskulaite